TransThera Sciences (Nanjing), Inc. (HKG:2617)

HKG:2617 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	-	1.18	0.12
Revenue Growth (YoY)	-	852.42%	-
Gross Profit	-	1.18	0.12
Selling, General & Admin	47.74	39.22	49.95
Research & Development	244	344.48	262.51
Other Operating Expenses	0.03	0.01	0.02
Operating Expenses	291.77	383.7	312.48
Operating Income	-291.77	-382.52	-312.36
Interest Expense	-0.2	-0.25	-0.18
Interest & Investment Income	2.17	12.16	6.02
Currency Exchange Gain (Loss)	-0.4	3.01	27.72
Other Non Operating Income (Expenses)	4.91	10.11	12.57
EBT Excluding Unusual Items	-285.29	-357.49	-266.24
Gain (Loss) on Sale of Investments	10.68	14.09	14.3
Gain (Loss) on Sale of Assets	-0	-0	-0.01
Pretax Income	-274.61	-343.39	-251.94
Net Income	-274.61	-343.39	-251.94
Net Income to Common	-274.61	-343.39	-251.94
Shares Outstanding (Basic)	382	381	360
Shares Outstanding (Diluted)	382	381	360
Shares Change (YoY)	0.06%	5.83%	-
EPS (Basic)	-0.72	-0.90	-0.70
EPS (Diluted)	-0.72	-0.90	-0.70
Free Cash Flow	-271.96	-322.81	-238.91
Free Cash Flow Per Share	-0.71	-0.85	-0.66
Gross Margin	-	100.00%	100.00%
Operating Margin	-	-32389.58%	-251900.00%
Profit Margin	-	-29076.54%	-203180.65%
Free Cash Flow Margin	-	-27333.78%	-192667.74%
EBITDA	-288.85	-378.87	-306.29
D&A For EBITDA	2.92	3.66	6.07
EBIT	-291.77	-382.52	-312.36

Source: S&P Global Market Intelligence. Standard template. Financial Sources.